1. Home
  2. SOUN vs TRVI Comparison

SOUN vs TRVI Comparison

Compare SOUN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SoundHound AI Inc

SOUN

SoundHound AI Inc

HOLD

Current Price

$3.09

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

SELL

Current Price

$13.19

Market Cap

1.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SOUN
TRVI
Founded
2005
2011
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
SOUN
TRVI
Price
$3.09
$13.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
11
Target Price
$12.00
★ $28.18
AVG Volume (30 Days)
★ 14.7M
1.5M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 73.08
31.91
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$60.18
N/A
Revenue Next Year
$43.27
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.20
$9.82
52 Week High
$13.19
$20.22

Technical Indicators

Market Signals
Indicator
SOUN
TRVI
Relative Strength Index (RSI) 17.11 45.40
Support Level N/A $13.00
Resistance Level $8.97 $13.55
Average True Range (ATR) 0.24 0.92
MACD -0.05 0.00
Stochastic Oscillator 5.36 17.43

Price Performance

Historical Comparison
SOUN
TRVI

About SOUN SoundHound AI Inc

SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: